The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...